Novartis oncology vet Stefan Scherer joins biotech migration to head clinical work, CAR-T partnership at Cellectis
Cellectis $CLLS has been busy since Allogene Therapeutics launched in April with a Pfizer deal that made them overnight partners, raising $164 million to hustle its off-the-shelf CAR-T therapies along the clinic. And it’s now hired a Novartis veteran to bolster that accelerated timeline.
Stefan Scherer’s official title will be senior vice president clinical development and deputy chief medical officer, reporting to CMO and R&D chief Stéphane Depil from the French biotech’s New York office.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.